INSMED INC (INSM) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $2.18M; Additional Paid in CapitalUSD $6.57B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.37M; Retained Earnings (Accumulated Deficit)USD $-5.81B.
- 2026-03-31: Common Stock, Value, IssuedUSD $2.17M; Additional Paid in CapitalUSD $6.50B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.00K; Retained Earnings (Accumulated Deficit)USD $-5.80B.
- 2025-12-31: Common Stock, Value, IssuedUSD $2.14M; Additional Paid in CapitalUSD $6.37B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.46M; Retained Earnings (Accumulated Deficit)USD $-5.64B.
- 2025-09-30: Common Stock, Value, IssuedUSD $2.13M; Additional Paid in CapitalUSD $6.25B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.00M; Retained Earnings (Accumulated Deficit)USD $-5.31B.
INSMED INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.18M | $6.57B | $-3.37M | $-5.81B | $757.49M | 3 month · $41.25M 6 month · $87.01M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $2.17M | $6.50B | $4.00K | $-5.80B | $704.85M | 3 month · $45.75M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $2.14M | $6.37B | $1.46M | $-5.64B | $738.98M | 12 month · $152.71M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $2.13M | $6.25B | $2.00M | $-5.31B | $945.57M | 3 month · $31.43M 9 month · $113.67M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $2.11M | $6.18B | $1.73M | $-4.94B | $1.25B | 3 month · $42.98M 6 month · $82.24M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.82M | $4.71B | $-902.00K | $-4.62B | $99.16M | 3 month · $39.26M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.79M | $4.65B | $-2.29M | $-4.36B | $285.38M | 12 month · $96.83M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $1.79M | $4.61B | $547.00K | $-4.12B | $483.42M | 3 month · $25.55M 9 month · $70.28M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $1.67M | $3.94B | $-2.83M | $-3.90B | $38.82M | 3 month · $23.29M 6 month · $44.74M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $1.49M | $3.14B | $-1.64M | $-3.60B | $-464.81M | 3 month · $21.45M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.48M | $3.11B | $-745.00K | $-3.45B | $-331.92M | 12 month · $74.78M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.43M | $2.97B | $-2.08M | $-3.26B | $-289.36M | 3 month · $19.99M 9 month · $54.80M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $1.43M | $2.95B | $-1.25M | $-3.10B | $-155.75M | 3 month · $18.36M 6 month · $34.80M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $1.36M | $2.81B | $1.08M | $-2.86B | $-44.65M | 3 month · $16.44M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.36M | $2.78B | $756.00K | $-2.70B | $87.95M | 12 month · $57.69M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $1.22M | $2.51B | $-1.39M | $-2.54B | $-29.96M | 3 month · $15.65M 9 month · $42.74M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $1.20M | $2.45B | $-929.00K | $-2.41B | $44.24M | 3 month · $14.26M 6 month · $27.08M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $1.19M | $2.43B | $-230.00K | $-2.31B | $119.88M | 3 month · $12.82M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $1.19M | $2.67B | $968.00K | $-2.27B | $410.47M | 12 month · $46.02M | (m) | (m) | 12 month · $196.36M | 12 month · $37.85M |
| 2021-09-30 | $1.18M | $2.66B | $100.00K | $-2.15B | $504.84M | 3 month · $12.23M 9 month · $34.50M | (m) | (m) | 3 month · $311.00K 9 month · $196.37M | 9 month · $37.85M |
| 2021-06-30 | $1.15M | $2.57B | $424.00K | $-2.04B | $531.05M | 3 month · $11.73M 6 month · $22.27M | (m) | (m) | 3 month · $196.06M 6 month · $196.06M | 3 month · $37.85M 6 month · $37.85M |
| 2021-03-31 | $1.03M | $2.12B | $90.00K | $-1.92B | $201.64M | 3 month · $10.54M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $1.03M | $2.11B | $193.00K | $-1.83B | $275.88M | 12 month · $36.16M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $1.02M | $2.08B | $114.00K | $-1.73B | $357.06M | 3 month · $8.91M 9 month · $27.38M | (m) | (m) | (m) | (m) |
| 2020-06-30 | $1.01M | $2.07B | $-98.00K | $-1.66B | $405.32M | 3 month · $9.47M 6 month · $18.47M | (m) | (m) | (m) | (m) |
| 2020-03-31 | $899.00K | $1.81B | $-47.00K | $-1.60B | $206.70M | 3 month · $9.00M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $897.00K | $1.80B | $-10.00K | $-1.54B | $261.67M | 12 month · $26.97M | (m) | (m) | 12 month · $261.07M | (m) |
| 2019-09-30 | $893.00K | $1.79B | $-8.00K | $-1.48B | $304.04M | 3 month · $6.79M 9 month · $21.08M | (m) | (m) | (m) | (m) |
| 2019-06-30 | $892.00K | $1.78B | $-7.00K | $-1.42B | $356.57M | 3 month · $7.35M 6 month · $14.29M | (m) | (m) | (m) | (m) |
| 2019-03-31 | $776.00K | $1.50B | $30.00K | $-1.36B | $144.14M | 3 month · $6.94M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $773.00K | $1.49B | $-9.00K | $-1.28B | $208.27M | 12 month · $26.24M | (m) | (m) | 12 month · $136.43M | (m) |
| 2018-09-30 | $771.00K | $1.48B | $20.00K | $-1.19B | $291.41M | 3 month · $7.90M 9 month · $20.20M | (m) | (m) | 9 month · $136.43M | (m) |
| 2018-06-30 | $770.00K | $1.47B | $18.00K | $-1.10B | $370.64M | 3 month · $6.63M 6 month · $12.30M | (m) | (m) | 3 month · $-29.00K 6 month · $136.43M | (m) |
| 2018-03-31 | $766.00K | $1.46B | $39.00K | $-1.03B | $434.86M | 3 month · $5.67M | (m) | (m) | 3 month · $136.46M | (m) |
| 2017-12-31 | $766.00K | $1.32B | $-3.00K | $-957.88M | $361.06M | 12 month · $18.07M | (m) | (m) | (m) | (m) |
| 2017-09-30 | $766.00K | $1.31B | $34.00K | $-892.50M | $421.31M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $624.00K | $930.18M | $-42.00K | $-847.32M | $83.44M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $621.00K | $923.76M | $-47.00K | $-802.65M | $121.68M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $620.00K | $919.16M | $-65.00K | $-765.24M | $154.48M | 12 month · $18.04M | (m) | (m) | (m) | (m) |
| 2016-09-30 | $619.00K | $914.05M | $-5.00K | $-696.83M | $217.83M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $619.00K | $909.00M | $12.00K | $-659.07M | $250.56M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $619.00K | $904.34M | $-3.00K | $-622.50M | $282.46M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $618.00K | $900.04M | (m) | $-588.96M | $311.70M | 12 month · $15.59M | (m) | (m) | (m) | (m) |
| 2015-09-30 | $618.00K | $896.10M | (m) | $-557.72M | $339.00M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $617.00K | $891.48M | (m) | $-526.76M | $365.34M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $500.00K | $662.51M | (m) | $-498.15M | $164.87M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $498.00K | $656.52M | (m) | $-470.78M | $186.24M | 12 month · $11.33M | (m) | (m) | (m) | (m) |
| 2014-09-30 | $496.00K | $651.90M | (m) | $-453.13M | $199.27M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $393.00K | $540.30M | (m) | $-429.14M | $111.55M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $393.00K | $537.26M | (m) | $-405.92M | $131.74M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $391.00K | $534.55M | (m) | $-391.62M | $143.32M | 12 month · $6.50M | (m) | (m) | (m) | (m) |
| 2013-09-30 | $391.00K | $532.14M | (m) | $-375.41M | $157.12M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $320.00K | $462.94M | (m) | $-358.08M | $105.18M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $316.00K | $455.73M | (m) | $-349.23M | $107.61M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $315.00K | $455.32M | (m) | $-335.55M | $120.88M | 12 month · $1.78M | (m) | $0.00 | (m) | (m) |
| 2012-09-30 | $312.00K | $455.56M | (m) | $-320.10M | $136.61M | (m) | (m) | $835.00K | (m) | (m) |
| 2012-06-30 | $249.00K | $429.55M | (m) | $-310.71M | $119.72M | (m) | (m) | $636.00K | (m) | (m) |
| 2012-03-31 | $249.00K | $428.24M | (m) | $-301.02M | $128.13M | (m) | (m) | $666.00K | (m) | (m) |
| 2011-12-31 | $248.00K | $427.74M | (m) | $-294.17M | $134.27M | 12 month · $1.60M | $0.00 | $450.00K | (m) | (m) |
| 2011-09-30 | $248.00K | $427.23M | (m) | $-286.01M | $142.34M | (m) | $0.00 | $871.00K | (m) | (m) |
| 2011-06-30 | $248.00K | $426.80M | (m) | $-251.42M | $176.74M | (m) | $0.00 | $1.12M | (m) | (m) |
| 2010-12-31 | $1.56M | $423.88M | (m) | $-234.51M | $192.84M | 12 month · $366.00K | $918.00K | $993.00K | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | $123.91M | 12 month · $1.15M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | $-2.82M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |